bluebird bioBLUE
BLUE
About: bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Employees: 375
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
9% less funds holding
Funds holding: 149 [Q2] → 136 (-13) [Q3]
8.78% less ownership
Funds ownership: 40.93% [Q2] → 32.15% (-8.78%) [Q3]
22% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 45
40% less call options, than puts
Call options by funds: $295K | Put options by funds: $492K
43% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 30
59% less capital invested
Capital invested by funds: $78.8M [Q2] → $32.7M (-$46.1M) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
18%
upside
Avg. target
$43
400%
upside
High target
$80
841%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target | 841%upside $80 | Sector Perform Reiterated | 15 Nov 2024 |
B of A Securities Jason Gerberry 43% 1-year accuracy 9 / 21 met price target | 18%upside $10 | Neutral Downgraded | 15 Nov 2024 |
Barclays Gena Wang 13% 1-year accuracy 4 / 30 met price target | 371%upside $40 | Overweight Maintained | 15 Nov 2024 |
Wells Fargo Yanan Zhu 6% 1-year accuracy 1 / 17 met price target | 371%upside $40 | Equal-Weight Maintained | 25 Sept 2024 |
Financial journalist opinion
Based on 5 articles about BLUE published over the past 30 days
Neutral
Business Wire
1 week ago
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation on Sunday, December 8 at 9:30 a.m. Pacific Time and a poster presentation on Sunday, December 8 at 6 p.
Neutral
Business Wire
2 weeks ago
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. “Updated follow-up data of up to 10 years showed that patients treated with beti-cel in clinical trials experi.
Neutral
Business Wire
2 weeks ago
bluebird bio Announces 1-for-20 Reverse Stock Split
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company's common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primary goal of the Reverse Stock Split is to increase the per share market price of the Company's common st.
Neutral
Business Wire
2 weeks ago
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs). “Ensuring timely, equitable.
Negative
Reuters
3 weeks ago
FDA investigates risk of blood cancers from bluebird bio's gene therapy
The U.S. Food and Drug Administration said on Wednesday it is investigating reports of blood cancers in patients who were treated with bluebird bio's gene therapy Skysona.
Positive
Seeking Alpha
1 month ago
My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys
Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks included Blackstone Secured Lending, Goldman Sachs BDC, and Midcap Financial Investment Corporation.
Negative
Benzinga
1 month ago
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
On Thursday, Bluebird Bio Inc. BLUE reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents.
Negative
Proactive Investors
1 month ago
bluebird bio downgraded by Bank of America, shares tumble
bluebird bio Inc (NASDAQ:BLUE) shares shed more than 11% on Friday after the Massachusetts-based biotech company developing gene therapies for severe genetic diseases was downgraded by Bank of America analysts. The analysts downgraded the company to ‘Neutral' and lowered their price target to $0.50 from $3 on their belief its key product launch, Lyfgenia for sick cell disease (SCD), will ramp slower and achieve lower peak revenue.
Neutral
Seeking Alpha
1 month ago
bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript
bluebird bio, Inc. (NASDAQ:BLUE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director, Investor Relations Andrew Obenshain - Chief Executive Officer Tom Klima - Chief Commercial & Operating Officer James Sterling - Chief Financial Officer Conference Call Participants Jack Allen - Baird Gena Wang - Barclays Jason Gerberry - Bank of America CJ Yeh - Leerink Partners Eric Schmidt - Cantor Fitzgerald Sami Corwin - William Blair Operator Good morning, ladies and gentlemen. Thank you for standing by.
Negative
Zacks Investment Research
1 month ago
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
Bluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago.
Charts implemented using Lightweight Charts™